Clinical Trial Update: ABL001 for the Treatment of Chronic Myeloid Leukemia in Patients Who Are on Therapy With Tyrosine Kinase Inhibitor [Phase 2]

View source ↗

Summary

A Phase 2 trial of ABL001 (asciminib) for chronic myeloid leukemia patients on tyrosine kinase inhibitors was terminated, and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• ABL001 (asciminib) (asciminib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Philadelphia Chromosome Negative, BCR-ABL1 Positive Chronic Myelogenous Leukemia | Phase 2 | Status: TERMINATED | Results posted: 2026-01-09